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ABSTRACT  
CONTEXT: In observational studies low serum 25-hydroxyvitamin D (25-OHD) 
concentration is associated with an increased risk of type 2 diabetes mellitus (DM). 
Increasing serum 25-OHD may have beneficial effects on insulin resistance or beta-
cell function. Cross-sectional studies utilising sub-optimal methods for assessment of 
insulin sensitivity and serum 25-OHD concentration provide conflicting results. 
OBJECTIVE: This study examined the relationship between serum 25-OHD 
concentration and insulin resistance in healthy overweight individuals at increased 
risk of cardiovascular disease, using optimal assessment techniques. 
METHODS: 92 subjects (mean age 56.0, SD 6.0 years), who were healthy but 
overweight (mean BMI 30.9, SD 2.3 kg/m2) underwent assessments of insulin 
sensitivity (two-step euglycaemic hyperinsulinaemic clamp, HOMA2-IR), beta-cell 
function (HOMA2%B), serum 25-OHD concentration and body composition (DEXA).  
RESULTS: Mean total 25-OHD concentration was 32.2, range 21.8 – 46.6 nmol/L. 
No association was demonstrated between serum 25-OHD concentration and insulin 
resistance.  
CONCLUSIONS: In this study using optimal assessment techniques to measure 25-
OHD concentration, insulin sensitivity and body composition, there was no 
association between serum 25-OHD concentration and insulin resistance in healthy, 
overweight individuals at high risk of developing cardiovascular disease. This study 
suggests the documented inverse association between serum 25-OHD concentration 
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and risk of type 2 DM is not mediated by a relationship between serum 25-OHD 
concentration and insulin resistance.  
  
pg. 5 
 
INTRODUCTION 
Vitamin D is a steroid hormone, which in active form binds to the vitamin D receptor. 
In observational studies low serum 25-hydroxyvitamin D (25-OHD) concentrations 
are associated with an increased risk of type 2 diabetes mellitus (DM) (1), a 
relationship that may be mediated via an effect on insulin resistance. Insulin 
resistance is defined as a reduced biological response to insulin (2). It is strongly 
associated with cardiovascular disease (CVD), is a characteristic feature of type 2 
DM (3), and its attenuation may reduce the incidence of type 2 DM and CVD.  
A variety of methods are used to assess insulin sensitivity, each having strengths 
and weaknesses, with the euglycaemic hyperinsulinaemic clamp technique 
considered the “gold standard” method of assessment (4). Most cross-sectional 
studies examining the relationship between 25-OHD concentration and insulin 
resistance have used surrogate markers of insulin resistance (1). Only four cross-
sectional studies with mixed cohorts (and size, n=39, n=38, n=112, n=76) have used 
the euglycaemic hyperinsulinaemic clamp technique with all four demonstrating an 
inverse association with serum 25-OHD concentration (5-8).  
Serum 25-OHD is the major circulating form of vitamin D and is widely considered to 
be the best indicator of vitamin D status (9). Different assay techniques for 
measuring 25-OHD result in variation of up to 20% above or below those obtained 
using the optimal technique of high-performance liquid chromatography and tandem 
mass spectrometry, which includes measurement of both the D2 and the D3 
isoforms (10). 
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Obesity and insulin resistance are associated (11). The location of body fat is also 
important, with subjects with an android distribution of body fat having greater insulin 
resistance than those with a gynoid distribution (12). The relationship between 
obesity and serum 25-OHD concentration is complex. Serum 25-OHD 
concentrations decrease with increasing adiposity (13). Many of the studies 
examining the association between 25-OHD and insulin resistance have used body 
mass index (BMI) as an indirect measure of adiposity. In this study we measured 
body composition using a whole body Dual Energy X-ray Absorptiometry (DEXA) 
scan. 
The aim of the present study was to examine the relationship between serum 25-
OHD and insulin resistance in healthy but overweight individuals at increased risk of 
cardiovascular disease, using optimal techniques for the assessment of insulin 
sensitivity and 25-OHD concentration and controlling for body composition. 
 
MATERIALS AND METHODS  
Study overview  
The data analysed in this study were collected at baseline from subjects in the 
“dose-response effect of fruit and vegetables on insulin resistance in healthy people 
who are overweight and at high risk of cardiovascular disease” trial. Ethical approval 
for this randomised controlled trial (RCT) was received from the Office for Research 
Ethics Committees Northern Ireland (ORECNI) and the study protocol was registered 
on ClinicalTrials.gov (trial registration no. NCT00874341). Methods and results have 
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been previously published (14). Data from 92 subjects who completed a two-step 
euglycaemic hyperinsulinaemic clamp were analysed.  
 
Subject recruitment and screening  
Between April 2009 and February 2011, subjects were recruited from the general 
population via press release, intranet advertisements within Belfast Health and 
Social Care Trust and Queen’s University Belfast, and from hospital outpatient 
clinics. Interested participants were screened for eligibility. Inclusion criteria – CVD 
risk of ≥20% over 10 years as defined by Joint British Societies’ Guidelines on 
prevention of CVD in clinical practice (15), BMI ≥ 27 kg/m2 and ≤ 35 kg/m2, habitual 
fruit and vegetable intake ≤2 portions per day. Exclusion criteria - DM, established 
CVD, surgery within previous three months, aspirin use, psychiatric problems, taking 
medication known to affect nutrient metabolism, pregnant or lactating, excessive 
alcohol consumption, taking antioxidant supplements, food sensitivities that would 
interfere with a tolerance to fruit and vegetables, medical conditions or dietary 
restrictions that would substantially limit ability to complete the study requirements, 
following a weight loss diet, unwillingness or inability to modify current diet, women 
of childbearing age not taking the contraceptive pill. 
 
Study assessments 
Assessments were performed at the Regional Centre for Endocrinology and 
Diabetes, Royal Victoria Hospital, Belfast. Blood pressure (BP) was measured using 
an oscillometric Meditech ABPM-04 ambulatory BP system (P.M.S. (Instruments) 
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Ltd, Berkshire, UK).  Height, weight, waist and hip circumference were recorded. 
Body composition was measured using a DEXA scan. All scans were performed by a 
trained radiographer using a Lunar Prodigy Pro DEXA scanner (GE Medical 
Systems, Madison, WI). 
A two-step euglycaemic hyperinsulinaemic clamp combined with infusion of [3-3H] 
glucose was performed as previously described, aiming for a target plasma glucose 
concentration of 5.3 mmol/L (14). Briefly, a cannula was inserted into the left arm for 
infusions and in the right arm for samples. The right hand was placed in a 
temperature-controlled plexiglass box (550C) to arterialise the venous blood. During 
a 2-hour equilibration period (-120 – 0 mins), a primed continuous infusion of [3-3H] 
glucose was administered. Initial tracer prime was adjusted, based on fasting plasma 
glucose concentration (16). A two-step sequential continuous infusion of insulin was 
administered: 0.4mU/kg/min (step 1, 0 - 120 mins), then 2.0 mU/kg/min (step 2, 120-
240 mins). Plasma glucose concentration was measured at 5 minute intervals on a 
bedside analyser (Beckman glucose analyser 2, Beckman RIIC Ltd., High Wycombe, 
UK) and maintained at the target plasma glucose concentration of 5.3 mmol/L by 
alternating rates of exogenous 20% glucose infusion. Exogenous glucose was pre-
labelled with [3-3H] glucose to match the predicted basal glucose specific activity as 
described, with the modification that the primed continuous tracer infusion was 
decreased to 50% of initial rate after 20 mins and to 25% of initial rate after 140 mins 
of insulin infusion (to maintain tracer steady state)(16).  
Insulin resistance was assessed using exogenous glucose infusion rate (GIR) 
required to maintain euglycaemia corrected for body weight and for fat free body 
mass. The isotope dilution method was used to allow measurement of endogenous 
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glucose production (EGP), rate of appearance of glucose in the peripheral circulation 
(Ra), and rate of disappearance or whole body uptake of glucose (Rd). 
 
Laboratory analysis 
All samples were collected on the day of the euglycaemic hyperinsulinaemic clamp. 
All samples were processed and stored at -80°C within 2 hours of collection. Assays 
were standardised against appropriate National Institute of Standards and 
Technology (NIST) control materials. Serum insulin was measured by enzyme linked 
immunosorbent assay (ELISA) (Abbot IMx; Abbott Laboratories, Berkshire, U.K.). 
Plasma glucose was measured using an automated glucose oxidase method using a 
Beckman glucose analyser 2 (Beckman RIIC Ltd.,High Wycombe, UK). The average 
of a minimum of 3 samples (4 were collected on each subject) of fasting glucose and 
insulin were used to calculate HOMA-IR and HOMA%B score (17). HOMA2-IR and 
HOMA2%B were calculated using an online calculator, accessed via the University 
of Oxford Diabetes Trials Unit website (www.dtu.ox.ac.uk/homacalculator/index.php) 
(18). Lipids were measured using a standard enzymatic colorimetric assay and 
serum calcium, phosphate and albumin were measured using a photometric method 
on an automated Roche Cobas 8000 Modular system biochemical analyser (Roche 
Diagnostics, West Sussex, UK). Serum concentrations of 25-OHD2&3 were measured 
by means of liquid chromatography tandem mass spectrometry (LC-MS/MS) and 
results presented as total 25-OHD (19).  
 
Statistical methods 
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All statistical analyses were carried out using SPSS for Windows version 17.0 (SPSS 
Inc, Chicago, IL). Normally distributed continuous variables are summarised as 
arithmetic mean +/- standard deviation. Categorical variables are reported as 
percentages. Skewed variables were logarithmically transformed to allow parametric 
analysis and are summarised using the geometric mean and interquartile range. In 
the entire cohort the degree of linear association between total 25-OHD 
concentration and selected variables was assessed using Pearson’s correlation 
coefficients. The study size was sufficient to give 90% power to detect as statistically 
significant (p<0.05, two-tailed) a correlation coefficient of 0.33 or greater. To adjust 
for the possibility of confounding factors, including body composition, partial 
correlation analysis was performed. The cohort of 92 subjects was divided into three 
sub-groups based on 25-OHD concentration (deficient (25-OHD concentration < 25 
nmol/L), insufficient (25-OHD concentration 25 - 50 nmol/L) and adequate (25-OHD 
concentration > 50 nmol/L), using UK Department of Health criteria for adequacy of 
vitamin D (20)). The three sub-groups were compared using one way analysis of 
variance (ANOVA) for continuous variables and chi-squared test for categorical 
variables.  
 
RESULTS 
Subject characteristics 
Subject characteristics are summarised in Table 1. As expected from the inclusion 
and exclusion criteria participants were overweight or obese (mean BMI 30.9, SD 2.3 
kg/m2) with mild to moderate hypertension (mean systolic BP 141, SD 15 mmHg, 
with 29% on antihypertensive therapy) and dyslipidaemia (mean total cholesterol 5.5, 
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SD 1.1 mmol/L and mean total cholesterol:HDL cholesterol ratio 4.4, range 3.6 – 5.2 
with 35% on pharmaceutical lipid-lowering therapy). Forty-two percent had 
prediabetes (21). Mean HbA1c was 36.3 mmol/mol, SD 3.3 mmol/mol (5.5%, SD 
0.3%). 
Mean serum total 25-OHD concentration was 32.2, range 21.8 – 46.6 nmol/L, almost 
entirely in the form of 25-OHD3. Serum 25-OHD2 concentration was highly skewed 
with 84 of 92 participants having a measured concentration below the assay 
detection level (0.895 nmol/L) and hence we report total 25-OHD concentration. 
Using UK Department of Health criteria for adequacy of vitamin D, 33% (n=30) were 
classed as deficient with measured serum vitamin D concentration less than 25 
nmol/L, 47% (n=43) insufficient with serum vitamin D concentration between 25 and 
50 nmol/L and only 20% (n=19) were classed as having adequate serum vitamin D 
(concentration greater than 50 nmol/L) (20). Serum calcium, phosphate, alkaline 
phosphatase and albumin concentrations for the 92 subjects were all within 
laboratory normal reference ranges.  
Insulin sensitivity was assessed using the 2-step euglycaemic hyperinsulinaemic 
clamp technique. Plasma glucose concentration was successfully maintained at the 
target concentration (5.3 mmol/L) with a coefficient of variation of less than 5%. 
Steady state serum insulin concentration and glucose infusion rate were successfully 
achieved during the plateau phases (between 90 and 120 minutes for step 1 and 
between 210 and 240 minutes for step 2).   
Association between serum 25-OHD concentration and insulin resistance 
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There was no statistically significant correlation between serum 25-OHD 
concentration and any measure of insulin sensitivity (including correction of glucose 
infusion rate for fat free mass, results not shown) (Table 2). Mean HOMA-IR was 1.8 
(1.3 – 2.5) and mean HOMA2-IR was 1.0 (0.7 – 1.3). Correlation coefficients were 
not statistically significant.  To examine the possibility of a non-linear association 
between serum 25-OHD concentration and measures of insulin sensitivity data were 
viewed graphically via scatter-plots with no association at any points along the range 
of serum 25-OHD concentrations (Figure 1 and 2).   
To examine the possibility of confounding, partial correlation analysis was performed 
(Table 3). No significant correlation between serum total 25-OHD concentration and 
exogenous glucose infusion rate required to maintain euglycaemia during the insulin 
infusion during step 1 (GIR step 1) or during step 2 (GIR step 2) was demonstrated 
after controlling for potential confounding variables (gender, season of sampling, 
age, weight, BMI, waist circumference, hip circumference, waist:hip ratio, total body 
fat percentage, android fat percentage, gynoid fat percentage, fasting plasma 
glucose concentration and fasting serum insulin concentration).  
25-OHD concentration subgroups  
To examine the possibility of a threshold effect the cohort of 92 subjects was divided 
into three subgroups based on serum 25-OHD concentration (Table 1). The 
subgroups were compared using one way ANOVA and no statistically significant 
trend was demonstrated with increasing serum 25-OHD concentration.  
Association between serum 25-OHD concentration and beta-cell function 
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Beta-cell function was assessed using HOMA%B and HOMA2%B with geometric 
mean values of 61.2 (44.7 – 83.4%) and 66.1 (53.1 – 82.5%) respectively. There 
were no significant correlations between serum 25-OHD concentration and 
measures of beta-cell function. Comparing the three subgroups based on serum 25-
OHD concentration, one way ANOVA demonstrated no significant between group 
difference or trend (results not shown). One subject had a serum 25-OHD 
concentration greater than 100 nmol/L, and repetition of all analyses after exclusion 
of this subject did not alter the negative findings.  
 
DISCUSSION 
Using optimal techniques to assess insulin sensitivity and serum 25-OHD 
concentration, this cross-sectional analysis demonstrated no relationship between 
serum 25-OHD concentration and insulin resistance in healthy, overweight 
individuals at high risk of cardiovascular disease.  
Findings with respect to insulin resistance are not inconsistent with previous reviews 
and meta-analyses (1,22,23). However, our results are largely discordant with the 
four cross-sectional studies which used the euglycaemic hyperinsulinaemic clamp 
technique to examine the relationship between serum 25-OHD concentration and 
insulin resistance, with all four reporting an inverse association (5-8). Muscogiuri et 
al demonstrated an inverse association between serum 25-OHD concentration and 
insulin resistance, which was no longer significant after correction for BMI. 
Compared to our study, the cohort was smaller (39 compared to 92 subjects), 
younger (mean age 41 compared to 56 years) and with differing HOMA-IR (mean 
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HOMA-IR 2.6 compared to 1.8). Subjects had a similar BMI (mean 30.1 +/- 5.4 kg/m2 
compared to 30.9 +/- 2.3 kg/m2) and both studies included participants with a range 
of glucose tolerance. However, the Muscogiuri et al study included several subjects 
with very high BMI (5 greater than 40 kg/m2). It is possible that the significant 
correlation in this small cohort between serum 25-OHD concentration and insulin 
resistance was driven by these individuals with a very high BMI (5). The same group 
also reported an inverse relationship between insulin resistance and serum 25-OHD 
concentration in 38 premenopausal women with polycystic ovarian syndrome. Again, 
after correction for total fat mass (assessed using DEXA) this association was no 
longer statistically significant (6). In a study of 112 postmenopausal French-
Canadian women, Morisset et al reported a correlation between insulin resistance 
and serum 25-OHD concentration. In this cohort, the association between serum 25-
OHD concentration and insulin resistance was independent of glucose tolerance 
status (numbers are not reported), but did not adjust for body composition, which 
had been assessed as part of the study (7). In a cohort of 76 women (42 with and 34 
without polycystic ovarian syndrome) Joham et al reported no association between 
serum 25-OHD and insulin resistance in the total group after adjustment for adiposity 
and age. However in the group of 42 with polycystic ovarian syndrome they report an 
association that remains significant after adjustment for age and body fat percentage 
(8). These four studies used a chemiluminescent assay to measure serum 25-OHD 
concentration, rather than the optimal technique of high-performance liquid 
chromatography and tandem mass spectrometry utilised in our study. We suggest 
that the well-defined cohort of healthy, overweight subjects at increased 
cardiovascular disease risk analysed in our study, may not be comparable to the 
cohorts analysed in these studies. 
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In contrast to several large studies, we demonstrated no association between insulin 
sensitivity measured by HOMA-IR and serum 25-OHD concentration (1). HOMA-IR 
may be altered by small perturbations in measured plasma glucose and serum 
insulin concentrations and should be based upon the mean of three separate 
samples (17). All samples in our study were processed in a single laboratory and 
were based on a mean of at least three fasting measurements. It is not clear if such 
stringent criteria were adhered to in other studies. It has been recommended that the 
computer modelling technique (HOMA2-IR) is used. We also demonstrated no 
association between serum 25-OHD concentration and HOMA2-IR (18). 
We demonstrate no association between serum 25-OHD concentration and beta-cell 
function (HOMA%B and HOMA2%B). A recent systematic review included five 
randomised controlled trials and found no significant effect of vitamin D 
supplementation on HOMA%B (23). However, studies using the more intensive 
hyperglycaemic clamp method have demonstrated a significant improvement in beta-
cell function in response to an increase in serum 25-OHD concentration (24,25). 
There are plausible mechanisms of association. Vitamin D exerts its effects via the 
vitamin D receptor which is found on many cells including beta-cells. The enzyme 
1α-hydroxylase which forms the active form of vitamin D is also located in beta-cells 
and vitamin D may mediate increased insulin secretion via increases in intracellular 
calcium through the phosphoinositide/protein kinase C pathway and facilitating 
calcium entry via calcium channels (26).  
Low serum 25-OHD concentrations are associated with an increased risk of 
development of type 2 DM (1). Based on the accumulated evidence from this 
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analysis and others (1), it seems unlikely that this relationship can be explained by 
an association between serum 25-OHD concentration and insulin resistance.  
Our study has a number of strengths. It is the only cross-sectional analysis 
examining the relationship between serum 25-OHD concentration and insulin 
resistance using optimal techniques to assess insulin sensitivity, body composition 
and serum 25-OHD concentration. Subjects were well characterised with 
anthropometry and accurate assessment of cardiovascular disease risk factors. All 
subjects had a DEXA scan to assess adiposity and body fat distribution.  
Plasma parathyroid hormone (PTH) concentration was not measured in the present 
study but is a possible confounder of an association between serum 25-OHD 
concentration and insulin resistance. There is an increased prevalence of type 2 DM 
in patients with primary hyperparathyroidism (27) and reduced insulin secretion and 
reduced insulin sensitivity have both been demonstrated in subjects with elevated 
plasma PTH concentrations (28). 
Whilst our study is large with respect to the euglycaemic hyperinsulinaemic clamp, 
studies using other techniques to assess insulin sensitivity may use larger numbers 
of subjects increasing statistical power. Our study size was sufficient to give 90% 
power to detect as statistically significant (p<0.05, two-tailed) a correlation coefficient 
of 0.33 or greater.  
We used a surrogate assessment of beta-cell function (HOMA%B and HOMA2%B) 
which reflects only changes in the fasting state. These techniques are arguably less 
sensitive than more intensive methods (such as the hyperglycaemic clamp) and we 
suggest that conclusions on beta-cell function based on our results are limited..  
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This study demonstrated no relationship between serum 25-OHD concentration and 
insulin resistance in healthy, overweight individuals at high risk of developing 
cardiovascular disease.  We suggest it is unlikely there is a significant association 
between serum 25-OHD concentration and insulin resistance. It remains possible 
that the documented association between serum 25-OHD concentration and risk of 
type 2 DM is mediated by an effect of serum 25-OHD concentration on beta-cell 
secretory response, rather than insulin resistance. A prospective, randomised 
placebo controlled trial of adequate duration on high risk individuals given sufficient 
vitamin D supplementation, utilising the euglycaemic hyperinsulinaemic clamp 
technique to assess insulin sensitivity and liquid chromatography tandem mass 
spectrometry to measure 25-OHD, with assessments performed before and after the 
intervention, is required to assess causality of these possible associations.  
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Figure 1: Scatterplot showing GIR step 1 against total vitamin D (25-OHD) 
concentration (n=89) 
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Figure 2: Scatterplot showing GIR step 2 against total vitamin D (25-OHD) 
concentration (n=92) 
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 Table 1: Subject characteristics (total group (n=92) and subgroups as defined 
by 25-OHD concentration 
 
 
Total group 
(n=92) 
Deficient 
(<25 nmol/L) 
(n=30 (33%)) 
Insufficient (25 - 
50 nmol/L) (n=43 
(47%)) 
Adequate 
(>50 nmol/L) 
(n=19 (20%)) 
Total 25-OHD 
concentration 
(nmol/L) 
32.2 (21.8 – 
46.6) 
18.5 (17.5 – 
21.8) 
35.9 (31.1 – 41.8) 
60.5 (51.3 – 
69.4) 
Gender (%), 
(n) 
Male 64% 
(59) 
Male 67% 
(20) 
 
Male 63% (27) 
 
Male 63% (12) 
Systolic 
Blood 
Pressure 
(mmHg) 
141 (15) 143 (13) 139 (16) 143 (18) 
Diastolic 
Blood 
Pressure 
(mmHg) 
93 (11) 92 (10) 93 (12) 95 (10) 
BMI (kg/m2) 30.9 (2.3) 
31.1 
(2.7) 
30.4 
(2.1) 
31.8 
(2.1) 
Fasting 
plasma 
glucose 
(mmol/L) 
5.5 (0.6) 5.9 (0.5) 5.8 (0.4) 5.9 (0.5) 
Fasting 
serum insulin 
(mU/L) 
7.1 (5.2 – 
9.4) 
7.8 (5.8 – 
9.9) 
6.7 (4.8 – 9.3) 6.7 (5.4 – 8.8) 
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GIR corrected 
for absolute 
weight Step 1 
(μmol/kg/min) 
6.6 (4.1 – 
10.6) 
6.2 (3.2 – 
10.0) 
7.3 (5.6 -10.6) 5.9 (3.3 -11.7) 
GIR corrected 
for absolute 
weight Step 2 
(μmol/kg/min) 
34.7 (28.0 – 
42.4) 
34.7 (28.0 – 
41.1) 
34.9 (29.1 – 42.4) 
34.2 (27.0 – 
43.1) 
EGP Basal 
(μmol/kg/min) 
10.4 (1.9) 10.5 (2.2) 10.4 (1.9) 10.5 (1.3) 
EGP Step 1 
(μmol/kg/min) 
5.6 (2.3) 5.4 (1.9) 5.2 (2.5) 7.0 (2.1) 
EGP Step 2 
(μmol/kg/min) 
1.8 (1.5 – 
5.6) 
1.2 (1.0 – 
4.7) 
2.1 (1.7 – 5.5) 2.3 (2.7 – 8.0) 
Rd Basal 
(μmol/kg/min) 
10.4 (1.8) 10.4 (2.1) 10.3 (1.9) 10.4 (1.1) 
Rd Step 1 
(μmol/kg/min) 
13.2 (10.5 – 
15.8) 
12.7 (9.8 – 
15.3) 
13.0 (10.5 – 15.3) 
14.6 (10.6 – 
19.5) 
Rd Step 2 
(μmol/kg/min) 
39.9 (11.1) 38.9 (9.8) 40.6 (11.6) 40.1 (12.4) 
pbetween group and ptrend were non-significant (p>0.05) 
 
Table 2: Correlation coefficients (Pearson (r)) between total 25-OHD and 
assessments of insulin resistance and beta-cell function 
 Whole group (n=92) 95% CI 
GIR corrected for -0.00 -0.21 - 0.26 
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absolute weight Step 1 
GIR corrected for 
absolute weight Step 2 
-0.00 -0.28 – 0.14 
EGP Basal 0.05 -0.16 – 0.32 
EGP Step1 0.19 -0.01 – 0.37 
EGP Step 2 0.14 -0.07 – 0.34 
Rd Basal 0.02 -0.19 – 0.26 
Rd Step 1 0.12 -0.12 – 0.33 
Rd Step 2 0.03 -0.22 – 0.21 
Ra Basal 0.05 -0.17 – 0.32 
Ra Step 1 0.14 -0.09 – 0.34 
Ra Step 2 0.01 -0.25 – 0.18 
All correlation coefficients were non-significant (p>0.05) 
Table 3: Partial correlation analysis for total 25-OHD concentration and GIR 
step 1 and for total 25-OHD concentration and GIR step 2 
 
Total 25-OHD concentration 
and GIR step 1 
 
Total 25-OHD concentration 
and GIR step 2 
 
Controlling for 
Correlation 
Coefficient (r) 
95% CI Correlation 
Coefficient (r) 
95% CI 
- -0.00 -0.21 – 0.26 -0.00 -0.28 – 0.14 
Gender 0.01 -0.22 – 0.21 -0.05 -0.25 – 0.13 
Age -0.01 -0.22 – 0.22 -0.06 -0.25 – 0.15 
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Weight 0.03 -0.20 – 0.25 -0.02 -0.25 – 0.18 
BMI 0.01 -0.22 – 0.26 -0.05 -0.25 – 0.16 
Waist 
Circumference 
0.03 -0.20 – 0.25 -0.02 -0.22 – 0.17 
Hip 
Circumference 
-0.00 -0.23 – 0.22 -0.06 -0.27 - 0.13 
Waist Hip Ratio 0.02 -0.22 – 0.25 -0.05 -0.25 – 0.15 
Total Body Fat 
Percentage 
0.00 -0.21 – 0.24 -0.06 -0.26 – 0.13 
Android Fat 
Percentage 
-0.01 -0.22 – 0.24 -0.08 -0.26 – 0.12 
Gynoid Fat 
Percentage 
0.01 -0.21 – 0.22 -0.05 -0.25 – 0.13 
Fasting 
Glucose 
-0.01 -0.25 – 0.22 -0.07 -0.27 – 0.11 
Fasting Insulin -0.11 -0.34 – 0.13 -0.19 -0.38 – 0.01 
All correlation coefficients were non-significant (p>0.05) 
 
